S&P 500   3,974.61 (+1.88%)
DOW   31,899.53 (+2.04%)
QQQ   293.51 (+1.67%)
AAPL   142.58 (+3.63%)
MSFT   260.37 (+3.09%)
FB   194.88 (+0.69%)
GOOGL   2,228.02 (+2.29%)
AMZN   2,142.99 (-0.41%)
TSLA   670.99 (+1.07%)
NVDA   167.77 (+0.50%)
BABA   86.71 (-0.09%)
NIO   15.76 (-4.14%)
AMD   94.59 (+1.17%)
CGC   5.20 (-5.80%)
MU   69.64 (+1.07%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.40 (+2.91%)
AMC   11.72 (-2.58%)
PFE   53.12 (+1.24%)
PYPL   81.20 (+0.82%)
NFLX   186.16 (-0.10%)
S&P 500   3,974.61 (+1.88%)
DOW   31,899.53 (+2.04%)
QQQ   293.51 (+1.67%)
AAPL   142.58 (+3.63%)
MSFT   260.37 (+3.09%)
FB   194.88 (+0.69%)
GOOGL   2,228.02 (+2.29%)
AMZN   2,142.99 (-0.41%)
TSLA   670.99 (+1.07%)
NVDA   167.77 (+0.50%)
BABA   86.71 (-0.09%)
NIO   15.76 (-4.14%)
AMD   94.59 (+1.17%)
CGC   5.20 (-5.80%)
MU   69.64 (+1.07%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.40 (+2.91%)
AMC   11.72 (-2.58%)
PFE   53.12 (+1.24%)
PYPL   81.20 (+0.82%)
NFLX   186.16 (-0.10%)
S&P 500   3,974.61 (+1.88%)
DOW   31,899.53 (+2.04%)
QQQ   293.51 (+1.67%)
AAPL   142.58 (+3.63%)
MSFT   260.37 (+3.09%)
FB   194.88 (+0.69%)
GOOGL   2,228.02 (+2.29%)
AMZN   2,142.99 (-0.41%)
TSLA   670.99 (+1.07%)
NVDA   167.77 (+0.50%)
BABA   86.71 (-0.09%)
NIO   15.76 (-4.14%)
AMD   94.59 (+1.17%)
CGC   5.20 (-5.80%)
MU   69.64 (+1.07%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.40 (+2.91%)
AMC   11.72 (-2.58%)
PFE   53.12 (+1.24%)
PYPL   81.20 (+0.82%)
NFLX   186.16 (-0.10%)
S&P 500   3,974.61 (+1.88%)
DOW   31,899.53 (+2.04%)
QQQ   293.51 (+1.67%)
AAPL   142.58 (+3.63%)
MSFT   260.37 (+3.09%)
FB   194.88 (+0.69%)
GOOGL   2,228.02 (+2.29%)
AMZN   2,142.99 (-0.41%)
TSLA   670.99 (+1.07%)
NVDA   167.77 (+0.50%)
BABA   86.71 (-0.09%)
NIO   15.76 (-4.14%)
AMD   94.59 (+1.17%)
CGC   5.20 (-5.80%)
MU   69.64 (+1.07%)
T   20.87 (+2.30%)
GE   75.96 (+0.94%)
F   12.84 (+2.72%)
DIS   105.40 (+2.91%)
AMC   11.72 (-2.58%)
PFE   53.12 (+1.24%)
PYPL   81.20 (+0.82%)
NFLX   186.16 (-0.10%)
OTCMKTS:POLXF

Polydex Pharmaceuticals (POLXF) Stock Forecast, Price & News

$0.80
0.00 (0.00%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.80
▼
$0.80
50-Day Range
$0.77
▼
$1.07
52-Week Range
$0.77
▼
$1.15
Volume
2 shs
Average Volume
4,663 shs
Market Capitalization
$2.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.44
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive POLXF News and Ratings via Email

Sign-up to receive the latest news and ratings for Polydex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Polydex Pharmaceuticals logo

About Polydex Pharmaceuticals

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product to treat cystic fibrosis, a genetic disease. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. The company sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.

Headlines

May 14, 2022 | americanbankingnews.com
Polydex Pharmaceuticals (OTCMKTS:POLXF) Share Price Passes Below 200 Day Moving Average of $0.97
May 4, 2022 | nz.finance.yahoo.com
Marshall Plan for Moms Mother's Day Mission: Cure Chronic Mom Guilt
May 3, 2022 | nz.finance.yahoo.com
QED Investors Hires Victoria Zuo to Help Scale Early Stage Team
May 3, 2022 | americanbankingnews.com
Polydex Pharmaceuticals (OTCMKTS:POLXF) Stock Price Crosses Below Two Hundred Day Moving Average of $0.96
January 29, 2022 | nasdaq.com
Polydex Pharmaceuticals Inc (POLXF)
January 26, 2022 | finance.yahoo.com
Polydex Pharmaceuticals Announces Collaboration with Termanox Water Treatment Solutions for novel use of Native Dextran
December 17, 2021 | nz.finance.yahoo.com
Global Plastic Recycling Market Witnessing an Upward Growth Trajectory—Projected to Reach USD 71.5 Billion by 2027 | BlueWeave
September 16, 2021 | nz.finance.yahoo.com
TP-Link Reveals Flagship Archer AX6600 Tri-Band Wi-Fi 6 Gaming Router for just $249.99
December 15, 2020 | finance.yahoo.com
Polydex Pharmaceuticals Issues Third Quarter Financial Results
June 15, 2020 | finance.yahoo.com
Polydex Pharmaceuticals Issues First Quarter Financial Results
April 30, 2020 | finance.yahoo.com
Polydex Pharmaceuticals Provides Year End Financial Report Closing the Year With A Strong Cash Position and Low Debt
March 29, 2020 | www.fool.com
Polydex Pharmaceuticals Limited (USA) (POLXF) - Cash Flow
December 16, 2019 | finance.yahoo.com
Polydex Pharmaceuticals Ltd. Reports 3rd Quarter Financial Results with continued improving gross margins
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Industrial inorganic chemicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:POLXF
Previous Symbol
CUSIP
N/A
CIK
317158
Web
www.polydex.com
Phone
(416) 755-2231
Fax
N/A
Employees
22
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.86 million
Price / Sales
0.56
Cash Flow
$0.15 per share
Price / Cash Flow
5.47
Book Value
$1.88 per share
Price / Book
0.43

Profitability

EPS (Most Recent Fiscal Year)
($0.07)
Net Income
$210 thousand
Net Margins
-4.99%
Pretax Margin
-4.94%
Return on Equity
-3.63%
Return on Assets
-3.08%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
4.00
Quick Ratio
3.01

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
3,432,000
Free Float
2,989,000
Market Cap
$2.75 million
Optionable
Not Optionable

Company Calendar

Today
5/23/2022
Fiscal Year End
1/31/2023

MarketRank™

Overall MarketRank™

1.22 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions

Who are Polydex Pharmaceuticals' key executives?
Polydex Pharmaceuticals' management team includes the following people:
  • Mr. George G. Usher, Chairman, CEO & Pres (Age 63)
  • Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 69)
  • Mr. David P. Jamestee C.A., CPA, Chief Financial Officer (Age 56)
What is Polydex Pharmaceuticals' stock symbol?

Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Polydex Pharmaceuticals' stock price today?

One share of POLXF stock can currently be purchased for approximately $0.80.

How much money does Polydex Pharmaceuticals make?

Polydex Pharmaceuticals has a market capitalization of $2.75 million and generates $4.86 million in revenue each year. The company earns $210 thousand in net income (profit) each year or ($0.07) on an earnings per share basis.

How many employees does Polydex Pharmaceuticals have?

Polydex Pharmaceuticals employs 22 workers across the globe.

What is Polydex Pharmaceuticals' official website?

The official website for Polydex Pharmaceuticals is www.polydex.com.

How can I contact Polydex Pharmaceuticals?

Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at (416) 755-2231 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.